Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Ning Shao; Yao Zhu; Ding Wei Ye

doi:10.1016/j.euf.2019.02.011

Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Eur Urol Focus. 2019 Sep;5(5):745-747. doi: 10.1016/j.euf.2019.02.011. Epub 2019 Feb 21.

Authors

Ning Shao¹, Yao Zhu², Ding Wei Ye³

Affiliations

¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
² Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: yaozhu09@fudan.edu.cn.
³ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: 17111230009@fudan.edu.cn.

PMID: 30797739
DOI: 10.1016/j.euf.2019.02.011

Abstract

1. mCRPC patients with gDDRm exhibit a good response to first abiraterone/enzalutamide treatments, despite this was not statistically significant. 2. The different detections of gDDRm and treatments (abiraterone or enzalutamide), indeed, are influential factors.

Publication types

Letter
Research Support, Non-U.S. Gov't
Review

MeSH terms

Androstenes / therapeutic use*
Benzamides
DNA Repair / genetics
Germ Cells
Humans
Male
Mutation
Neoplasm Metastasis
Nitriles
Phenylthiohydantoin / analogs & derivatives*
Phenylthiohydantoin / therapeutic use
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics
Prostatic Neoplasms, Castration-Resistant / pathology
Treatment Outcome

Substances

Androstenes
Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide
abiraterone